Compagnie Lombard Odier SCmA lessened its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 87.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,000 shares of the biotechnology company's stock after selling 57,000 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Aurinia Pharmaceuticals were worth $72,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the third quarter worth about $3,330,000. Barclays PLC lifted its holdings in shares of Aurinia Pharmaceuticals by 187.6% in the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after buying an additional 143,072 shares in the last quarter. PDT Partners LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 76.0% in the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company's stock worth $2,210,000 after buying an additional 130,204 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company's stock worth $5,454,000 after buying an additional 89,940 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock worth $21,587,000 after buying an additional 64,949 shares in the last quarter. Institutional investors own 36.83% of the company's stock.
Analysts Set New Price Targets
Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, February 10th.
View Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Price Performance
AUPH traded up $0.20 on Tuesday, reaching $7.99. The company had a trading volume of 1,033,061 shares, compared to its average volume of 1,263,882. The business has a 50 day simple moving average of $8.47 and a 200 day simple moving average of $7.66. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -53.26 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67.
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Read More
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
